Spotify has entered 2018 with a bang. Yesterday, news broke that Spotify was being hit with a $1.6 billion lawsuit. Then today, AXIOS reported that Spotify had filed IPO documents with the SEC at the end of December. The two journalists who broke these stories join Cheddar to break down the news and what's in store for Spotify.
Dan Primack of AXIOS explains that the company is pursuing a direct listing. This creates a unique path for the tech company that is distinctly different from the traditional IPO path. Primack reports that Spotify is targeting a Q1 public offering, and based on their current timeline, he thinks it is possible.
Eriq Gardner is the senior editor at The Hollywood Reporter and he broke the $1.6 billion lawsuit story. He reports that Spotify was sued by Wixen Music Publishing Inc last week for allegedly using thousands of songs without a license and proper compensation. Some of the artists under Wixen Publishing include Tom Petty, Neil Young, and the Doors. Gardner was not surprised by the lawsuit. He says that many record labels are fans of the music streaming company because they have deals that could lead to billions of dollars if the company goes public. However, as current law stands, music publishers have not benefitted from the rise in popularity of Spotify. This is why he was not surprised by the lawsuit.
Jay Hatfield, chief investment officer for ICAP, joined Cheddar News to discuss how markets are reacting to labor market news and what the Federal Reserve will do next in terms of interest rates.
Kristin Cavallari, who first gained fame as a cast member of the MTV reality show Laguna Beach, is now the founder of a beauty company called Uncommon James. Cheddar News anchor Hena Doba took a walk with Cavallari to discuss her many business ventures.
Heardle, the name-that-tune game inspired by the Wordle craze, is being dropped by Spotify less than a year after the music-streaming giant acquired it.
Moderna and Merck & Co. have developed a cancer vaccine that cuts the risk of death or recurrence of most deadly skin cancer by 44 percent compared to Keytruda on its own, according to researchers.
